Lawmakers on Thursday will hear testimony on a bill to lower the price of insulin drugs and supplies for more North Dakotans.

Surgeons are collaborating with obesity medicine physicians, turning to GLP-1s to help high BMI patients qualify for surgery.

Europe's STOXX 600 struggled for direction on Tuesday as rising industrials and financial services shares offset losses in ...

Insulin has long been the typical pharmacological go-to agent for gestational diabetes, the researchers pointed out, but oral ...

Kuykendall has been in his current role since July 2022. Interesting fact: He has worked with Novo Nordisk for more than 18 years, though not consecutively. Key number: Novo Nordisk is investing $4.1 ...

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

As previously reported, Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform with a price target of DKK 600, up from DKK ...

Bernstein upgraded Novo Nordisk (NVO) to Market Perform from Underperform.Don't Miss Our New Year's Offers:Discover the latest stocks ...

This article introduces the largest foundations in the world, fostering changes and improvements across various sectors to ...

Dual- and triple-agonist GLP-1s appear to achieve greater weight loss in an overview of clinical trials of approved and ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in cystic fibrosis, cancer and possibly chronic pain.